Why we built this.
We spent years building computational biology software used at biopharma organizations. That work put us close to translational and discovery teams across pharma, biotech, and academia. We saw the same pattern everywhere.
Most assets that move from preclinical to clinical fail. The warning signs are usually there in the data, but nobody has time to find them. Teams handle the routine parts: QC, normalization, basic stats. The bottleneck is the deeper work: comparing methods head to head, checking whether a biomarker holds across cohorts, following a weak signal across three datasets to see if it is real or noise. That work takes weeks of expert time. Most of it never gets done.
The signals that kill an asset in phase 2 are usually visible earlier, if someone has time to look.
So we built Inflexa to do that work. It runs more of the analysis than a person has time for: more methods, more comparisons, more follow-up. It generates hypotheses, then tests them against the data and against the literature. When datasets are large and time is short, humans miss things.
The output isn't a black box, and neither is the software. Every result links back to the data, the code, the method, and the model that produced it, and every citation in it is checked against PubMed and the other registries before it is printed. And the tool that produced it is open under Apache 2.0. You can read it, change it, run it on a machine we never see, and keep using it whatever happens to us.
A scientific result you cannot inspect is a result you are taking on trust. We would rather you didn't have to.